ABCL-647 The outcome of tisagenlecleucel (tisa-cel) CD-19 CAR-T cell therapy in NHL relapsed/refractory beyond second line of therapy, single-center data

According to data from a single-center retrospective analysis—presented during the 2023 Society of Hematologic Oncology Annual Meeting—patients with relapsed or refractory DLBCL who received tisagenlecleucel CD-19 CAR T-cell therapy experienced durable response rates similar to real-world and clinical trial data. The best overall response rate was 52%; 32% of patients had complete responses, 20% had partial responses, and 48% experienced disease progression. Post–CAR T-cell infusion, the main toxicities included cytokine release syndrome (88%, with 12% grade ≥3) and neurotoxicity (24%, with 20% grade ≥3).